Donoghoe Nicholas's Form 4 filing
AbbVie Inc. (ABBV) · filed Mar 22, 2024
- Accession no.
- 0001415889-24-008970
- Filed
- Mar 22, 2024
- Trade date
- Mar 20, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $3.72M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Donoghoe NicholasCIK 0001762951 | Officer (EVP, CHIEF BUS/STRAT OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2024 | Common Stock, $0.01 par value | SSaleDisposed | −21,082 | $176.30F1 | −$3,716,756.6 | 55,903 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.26 to $176.35, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.